335 related articles for article (PubMed ID: 33406435)
1. Small Molecule SARM1 Inhibitors Recapitulate the SARM1
Hughes RO; Bosanac T; Mao X; Engber TM; DiAntonio A; Milbrandt J; Devraj R; Krauss R
Cell Rep; 2021 Jan; 34(1):108588. PubMed ID: 33406435
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy.
Bosanac T; Hughes RO; Engber T; Devraj R; Brearley A; Danker K; Young K; Kopatz J; Hermann M; Berthemy A; Boyce S; Bentley J; Krauss R
Brain; 2021 Nov; 144(10):3226-3238. PubMed ID: 33964142
[TBL] [Abstract][Full Text] [Related]
3. cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons.
Sasaki Y; Engber TM; Hughes RO; Figley MD; Wu T; Bosanac T; Devraj R; Milbrandt J; Krauss R; DiAntonio A
Exp Neurol; 2020 Jul; 329():113252. PubMed ID: 32087251
[TBL] [Abstract][Full Text] [Related]
4. Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration.
Krauss R; Bosanac T; Devraj R; Engber T; Hughes RO
Trends Pharmacol Sci; 2020 Apr; 41(4):281-293. PubMed ID: 32107050
[TBL] [Abstract][Full Text] [Related]
5. Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice.
Geisler S; Doan RA; Strickland A; Huang X; Milbrandt J; DiAntonio A
Brain; 2016 Dec; 139(Pt 12):3092-3108. PubMed ID: 27797810
[TBL] [Abstract][Full Text] [Related]
6. The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD
Essuman K; Summers DW; Sasaki Y; Mao X; DiAntonio A; Milbrandt J
Neuron; 2017 Mar; 93(6):1334-1343.e5. PubMed ID: 28334607
[TBL] [Abstract][Full Text] [Related]
7. Sarm1 haploinsufficiency or low expression levels after antisense oligonucleotides delay programmed axon degeneration.
Gould SA; Gilley J; Ling K; Jafar-Nejad P; Rigo F; Coleman M
Cell Rep; 2021 Dec; 37(11):110108. PubMed ID: 34910914
[TBL] [Abstract][Full Text] [Related]
8. TIR Axons Apart: Unpredicted NADase Controls Axonal Degeneration.
Goldner R; Yaron A
Neuron; 2017 Mar; 93(6):1239-1241. PubMed ID: 28334598
[TBL] [Abstract][Full Text] [Related]
9. Novel role of SARM1 mediated axonal degeneration in the pathogenesis of rabies.
Sundaramoorthy V; Green D; Locke K; O'Brien CM; Dearnley M; Bingham J
PLoS Pathog; 2020 Feb; 16(2):e1008343. PubMed ID: 32069324
[TBL] [Abstract][Full Text] [Related]
10. Regulation of degenerative spheroids after injury.
Yong Y; Gamage K; Cushman C; Spano A; Deppmann C
Sci Rep; 2020 Sep; 10(1):15472. PubMed ID: 32963272
[TBL] [Abstract][Full Text] [Related]
11. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program.
Geisler S; Doan RA; Cheng GC; Cetinkaya-Fisgin A; Huang SX; Höke A; Milbrandt J; DiAntonio A
JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484833
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy targeting SARM1 blocks pathological axon degeneration in mice.
Geisler S; Huang SX; Strickland A; Doan RA; Summers DW; Mao X; Park J; DiAntonio A; Milbrandt J
J Exp Med; 2019 Feb; 216(2):294-303. PubMed ID: 30642945
[TBL] [Abstract][Full Text] [Related]
13. Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1.
Henninger N; Bouley J; Sikoglu EM; An J; Moore CM; King JA; Bowser R; Freeman MR; Brown RH
Brain; 2016 Apr; 139(Pt 4):1094-105. PubMed ID: 26912636
[TBL] [Abstract][Full Text] [Related]
14. Genetic inactivation of SARM1 axon degeneration pathway improves outcome trajectory after experimental traumatic brain injury based on pathological, radiological, and functional measures.
Bradshaw DV; Knutsen AK; Korotcov A; Sullivan GM; Radomski KL; Dardzinski BJ; Zi X; McDaniel DP; Armstrong RC
Acta Neuropathol Commun; 2021 May; 9(1):89. PubMed ID: 34001261
[TBL] [Abstract][Full Text] [Related]
15. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway.
Osterloh JM; Yang J; Rooney TM; Fox AN; Adalbert R; Powell EH; Sheehan AE; Avery MA; Hackett R; Logan MA; MacDonald JM; Ziegenfuss JS; Milde S; Hou YJ; Nathan C; Ding A; Brown RH; Conforti L; Coleman M; Tessier-Lavigne M; Züchner S; Freeman MR
Science; 2012 Jul; 337(6093):481-4. PubMed ID: 22678360
[TBL] [Abstract][Full Text] [Related]
16. Traumatic axonopathy in spinal tracts after impact acceleration head injury: Ultrastructural observations and evidence of SARM1-dependent axonal degeneration.
Alexandris AS; Lee Y; Lehar M; Alam Z; Samineni P; Tripathi SJ; Ryu J; Koliatsos VE
Exp Neurol; 2023 Jan; 359():114252. PubMed ID: 36244414
[TBL] [Abstract][Full Text] [Related]
17. The NAD
Jiang Y; Liu T; Lee CH; Chang Q; Yang J; Zhang Z
Nature; 2020 Dec; 588(7839):658-663. PubMed ID: 33053563
[TBL] [Abstract][Full Text] [Related]
18. Deregulated mitochondrial quality control, the heel of Achilles in elucidating the role of autophagy in SARM1-mediated axon degeneration.
Wang S; Zhang Y; Song M; Zhao X; Song F
J Neurosci Res; 2024 Jan; 102(1):e25292. PubMed ID: 38284842
[TBL] [Abstract][Full Text] [Related]
19. Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection.
Sasaki Y; Zhu J; Shi Y; Gu W; Kobe B; Ve T; DiAntonio A; Milbrandt J
Exp Neurol; 2021 Nov; 345():113842. PubMed ID: 34403688
[TBL] [Abstract][Full Text] [Related]
20. SARM1-mediated wallerian degeneration: A possible mechanism underlying organophosphorus-induced delayed neuropathy.
Song M; Kang K; Song F
Med Hypotheses; 2021 Oct; 155():110666. PubMed ID: 34455132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
